title: [Not Available].
abstract: Gabapentin is a structural analogue of GABA used in the treatment of the partial epilepsies of adult and child of more than 12 years, in monotherapy or in association with other anticonvulsant drugs. In association, gabapentin presents the advantage of not interfering with the other anticonvulsant drugs. The interindividual pharmacokinetic variability and the saturable absorption are, with the adaptation in case of renal insufficiency, the only arguments in favor of TDM. During clinical studies, the plasma concentrations of gabapentin were generally included between 2 and 20 mg/L. For this molecule, the level of proof of the interest of therapeutic drug monitoring was estimated in: possibly useful.
authors.affiliation: Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France. Electronic address: olivier.tribut@chu-rennes.fr.
authors.forename: Olivier
authors.initials: O
authors.lastname: Tribut
authors.affiliation: Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France.
authors.forename: Danièle
authors.initials: D
authors.lastname: Bentué-Ferrer
authors.affiliation: Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France.
authors.forename: Marie-Clémence
authors.initials: MC
authors.lastname: Verdier
keywords: gabapentin; gabapentine; suivi thérapeutique pharmacologique; therapeutic drug monitoring